suggests that lack of post-ASCT immunosurveillance may contribute to the risk of tumor relapse.
The high relapse rates that occur after autologous stem cell transplantation (ASCT) have been attributed to the failure of high-dose chemotherapy with or without radiotherapy to eliminate minimal residual disease. Recurrences often occur during the first year 1, 2 and may occur within 100 days post ASCT. 3 Results of post-ASCT immunorecovery studies have demonstrated that humoral (B cells) 4, 5 and cellmediated (T cells) 6, 7 components of the immune system are not fully recovered at the time of most tumor relapses. This suggests that lack of post-ASCT immunosurveillance may contribute to the risk of tumor relapse.
Overwhelming evidence from several post-ASCT immunorecovery studies demonstrated normal quantitative reconstitution of natural killer (NK) cells within 1 month after ASCT. [8] [9] [10] [11] [12] [13] NK cells comprise 5% to 8% of human peripheral blood lymphocytes and morphologically resemble large granular lymphocytes.
14 NK cells are capable of dual cytolytic activity. First, they are capable of spontaneous, antibody-independent, non-major histocompatibility complexrestricted cytotoxicity mediated by the binding of NK cell surface leukocyte function-associated antigen 1 (clusters of differentiation [CD]11aCD18) and CD2 to their target cell ligands, CD54 and CD58, respectively. 15 Second, they can mediate antibody-dependent cellular cytotoxicity by the binding of NK cell surface CD16 to their target cell ligands. 15 Several studies have shown the presence of infiltrating NK cells in solid tumors and lymphomas. [16] [17] [18] [19] [20] Preclinical studies have shown that NK cells eradicate and control tumor cell growth of leukemias and lymphoma. [21] [22] [23] Because NK cells recover early during the period when most tumor relapses occur post ASCT, our interest focused on regulation of NK cells as a method of immunotherapy to improve remission and cure rates by eradicating minimal residual disease by means of stimulated NK cells.
IL-2 is a 15-kDa glycoprotein that promotes proliferation and differentiation of helper T cells, cytotoxic T cells, and B cells and is necessary for acute and anamnestic adaptive immune responses. 24 IL-2 is an excellent candidate to be an immunomodulator for post-ASCT up-regulation of NK cells, because NK cells are unique in that they constitutively express IL-2 receptors; thus, they always react to IL-2. 25 NK cells have also interferon receptors in their cell membrane, and interferons have been shown to be effective up-regulators of NK-cell activity. [26] [27] [28] [29] Results of previous studies have demonstrated that IL-2 and IFN-␣ augment NK cell cytotoxicity. [30] [31] [32] [33] [34] The aim of our study was to determine whether IL-2 or IFN-␣ can up-regulate NK cell activity in vitro as early as 14 days after ASCT.
Patients and methods

Patient samples
This study was approved by the Institutional Review Board of Mayo Foundation. Twenty patients who were candidates for ASCT at Mayo Clinic were entered in the study from October 1999 until April 2000. Of these 20, 10 had multiple myeloma and 10 had non-Hodgkin lymphoma.
Preparation of mononuclear cells
Venous blood (30 ml) was drawn from every patient just before stem cell mobilization and collection and at 14 days post ASCT. Mononuclear cells were separated by gradient centrifugation on Ficol and washed and resuspended on RPMI 1640.
Immunophenotyping
Immunophenotyping of PBMCs was performed using a two-color direct staining of cells with mouse monoclonal antibodies. Fluorescein isothiocyanate-or phycoerythrincoupled antibodies (Becton Dickinson PharMingen, San Diego, CA, USA) were directed at CD2, CD3, CD4, CD8, CD16, CD19, CD25, CD56, and human leukocyte antigen D-related. Phenotypic analysis was performed with a FACStar PLUS flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) equipped with CONSORT 40 software (Becton Dickinson Biosciences, San Jose, CA, USA). Fluorescein isothiocyanate-and phycoerythrin-coupled isotype-matched immunoglobulins were used as controls.
NK cell cytotoxicity assay
The cytotoxicity of the cell preparations was tested against the NK-sensitive myeloid leukemia cell line K-562 in a 4-h sodium chromate 51 Cr release assay. Target cells were labeled with 100 Ci of 51 Cr for 4 h at 37°C. Washed target cells (1 million per well) were added to the wells of roundbottom 96-well plates (Falcon; Becton Dickinson) and incubated at effector-to-target cell ratios ranging from 50:1 to 6.25:1. Maximum release and spontaneous release were determined by incubating the target cells with 1% Triton X-100 (Sigma-Aldrich, Milwaukee, WI, USA) and medium alone, respectively. All determinations were made in triplicate. Radioactivity was counted with a COBRA gamma counter (Packard Instrument Company, Meriden, CT, USA) after using a Skatron supernatant harvester (Molecular Devices, Sunnyvale, CA, USA). The percentage of specific lysis was determined with this formula: % specific lysis = 
IL-2 and IFN-␣ dose-response curves
To identify the best in vitro cytokine dose to achieve maximum NK cell cytotoxicity, dose-response curves were determined for IL-2 and IFN-␣ for normal volunteers, for patients post engraftment, and for the human NK cell line NK-92 (American Type Culture Collection, Manassas, VA, USA). Samples in different dose ranges for IL-2 (66 IU/ml-18 million IU/ml) and IFN-␣ (25 IU/ml-3 million IU/ml) were incubated for 24 h in RPMI 1640, and the NK cell cytotoxicity assay was performed with a 50:1 effector-totarget ratio.
NK cell activity
NK cells were activated for cytotoxicity assays. For this purpose, PBMCs were cultured in RPMI 1640 for 24 h in the presence of 10 000 U of recombinant IL-2 and IFN-␣. Normal volunteers' PBMCs and human cell line NK-92 were used as controls with and without cytokines.
Maintenance of cell lines
Cell line K562 (NK-sensitive target, American Type Culture Collection) was maintained in continuous culture in RPMI 1640 medium supplemented with 1% glutamine and 5% heat-inactivated fetal calf serum. Human NK cell line NK-92 was maintained in continuous culture in RPMI 1640 supplemented with 100 U/ml of IL-2, 1% glutamine, 5% heat-inactivated fetal calf serum, and 1% sodium pyruvate.
Statistics
Significance levels were determined by the two-tailed Student's t-test.
Results
Patient characteristics
Our study included 16 males and four females (Table 1) . Median age was 58 years (range, 23-71 years). Diseases for which ASCT was performed included multiple myeloma (10 patients) and non-Hodgkin's lymphoma (large cell lymphoma, eight patients; T cell-rich B cell lymphoma, one patient; and mantle zone lymphoma, one patient). All patients who had multiple myeloma were conditioned with melphalan, 200 mg/m 2 , 1 day before transplantation. One patient also received samarium, 12 mCi/kg, on the 10th day before his ASCT. The patients who had non-Hodgkin's lymphoma were conditioned on the 6th day before ASCT with carmustine, 300 mg/m 2 ; on the fifth to the second day before ASCT with cytarabine, 100 mg/m 2 every 12 h, and with etoposide, 100 mg/m 2 every 12 h; and on the day before ASCT with melphalan, 140 mg/m 2 (BEAM). All patients achieved neutrophil engraftment and had absolute neutrophil counts of at least 0.5 × 10 Table 2 shows the phenotypic composition of PBMCs in normal controls and patients before transplantation and at day 14 post ASCT. Before transplantation and at day 14, the percentages of CD3 + , CD4 + , CD8 + , and CD19 + cells were low compared with those of normal controls. In contrast, the percentages of CD16 + CD56 + CD3 − cells (NK cell phenotypic markers) before transplantation were equal to or greater than those of the normal controls. At day 14, the percentages of CD16 + CD56 + CD3 − cells had recovered to levels that were equal to or greater than those of the normal controls. Figure 1 shows the dose-response curves for IL-2 and IFN-␣ for normal volunteers, for the human NK-cell line NK-92, and for patients 14 days post ASCT. All curves Bone Marrow Transplantation demonstrate that the maximum up-regulation of NK cell cytotoxicity occurred at 10 000 IU/ml for each cytokine. At higher concentrations, each cytokine produced marked down-regulation of NK cell cytotoxicity.
Immunophenotyping
IL-2 and IFN-␣ dose-response curves
NK cell activity
The incubation of PBMCs with IL-2 and IFN-␣ markedly increased NK cell activity (Figure 2) . When cytokine-and placebo (media)-treated effector PBMCs were compared, the differences in NK cytotoxicity were significant (effector-to-target ratio, 50:1, P Ͻ 0.0001). This effect by each cytokine was observed before transplantation and at 14 days post ASCT for all patients. The controls (normal volunteers and human NK cell line NK 92) demonstrated similar NK cell up-regulation by each cytokine. No statistical difference existed in up-regulation of NK cell activity by either cytokine between patients and controls (effectorto-target ratio, 50:1, P Ͻ 0.66).
Discussion
The delay in immunorecovery during the first year after transplantation of autologous stem cells supports the hypothesis that the high number of relapses during this period may be due in part to lack of effective immunosurveillance capable of containing or eradicating minimal residual disease during this period. For eight patients with B cell non-Hodgkin lymphoma who had autotransplantations with T cell-depleted CD34 + stem cells, Divine et al 35 showed a sustained quantitative deficiency for CD3 + , CD4 + , CD8 + , and CD19
+ cells up to 18 months post transplantation. Talmadge et al 36 showed a faster recovery for CD4 + , CD8 + , and CD19
+ cells for autologous peripheral stem cell transplantation than for ABMT in the first 100 days post transplantation, although levels were lower than those for normal controls.
The T and B cell functional recovery remains deficient for years post transplantation. [37] [38] [39] The delayed quantitative and functional recovery of humoral (B cells) and cellmediated (T cells) components of the immune system is evidence against their utility in immunotherapeutic strategies early post transplantation. In contrast, NK cell quantity and function return to normal within 30 days post transplantation. [40] [41] [42] The development of NK cells before T cell subsets from stem cells has been demonstrated in normal volunteers. Lotzova et al 43 
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cultured CD34
+ stem cells in long-term bone marrow culture from normal donor bone marrow. At 2 weeks, 80% of the lymphocyte subsets were CD56 + CD3 − (NK cells) compared with 10% of the T cell phenotype. Long-term bone marrow culture without IL-2 did not support the genesis of NK cells. These NK cells showed high cytotoxic efficacy against the K562 cell line. In a stroma-dependent long-term bone marrow culture system, Miller et al 44 The results of our study confirm the early recovery of NK cells post ASCT compared with that of humoral and cell-mediated immunity. However, compared with the results of other studies in which phenotypic NK cell analysis was performed at multiple intervals post transplantation, the results of our study show that quantities and function of NK cells return to normal as early as 14 days post ASCT.
Multiple preclinical studies have demonstrated doseresponse curves for up-regulation of NK cell activity with either IL-2 or IFN-␣. Talmadge et al 45 reported that lowdose IL-2 (100 U) achieved a greater cure rate than did a dose of 10 000 U for mice inoculated with mannan-binding lectin-2 lymphoma. Using murine splenic NK cells against the yeast artificial chromosome 1 lymphoma cell line, Kuribayashi et al 46 showed maximum NK cell cytotoxicity (40%) at concentrations of IL-2 and IFN-␣ of 10 000 U/ml. At greater concentrations, NK cell cytotoxicity decreased to 15%. Shaw et al 47 reported maximum NK cell activity (100 lytic units) by incubating normal volunteers' PBMCs with IL-2 at 3000 U/ml against a colorectal carcinoma cell line, LoVo. At higher concentrations, down-regulation of NK cell activity (60 lytic units) occurred.
Results of these studies corroborate our dose-response curves for normal volunteers, human NK cell line NK-92, and patients at day 14 post ASCT. Our in vitro data strongly support the concept that low-dose IL-2 and IFN-␣ result in maximum NK cell activity, and higher doses of IL-2 (18 million U) and IFN-␣ (3 million U) produce down-regulation of NK cell activity.
Studies with humans have shown that high-dose IL-2 given either intravenously or subcutaneously produces severe lymphopenia. Thompson et al 48 reported that nonselective, dose-dependent lymphopenia occurred in 22 patients treated with 2-h or 24-h infusions of IL-2 in doses ranging from 3 million U to 30 million U. The lymphopenia lasted 7 days after the last day of IL-2 therapy. NK cell activity was markedly decreased 24 h after the last dose of IL-2 compared with NK-cell activity before IL-2 therapy.
Higuchi et al 49 treated 16 patients post ABMT with intravenous induction IL-2 therapy for 5 days, with doses ranging from 3 to 4.5 million U/m 2 . Marked lymphopenia during the induction therapy was followed by a rebound lymphocytosis 24 h after termination of the induction treat- ABMT = autologous bone marrow transplant; ABPSCT = autologous blood peripheral stem cell transplant; ALL = acute lymphoblastic leukemia; Allo-BMT = allogeneic bone marrow transplant; AML = acute myelogenous leukemia; BMT = bone marrow transplant; CML = chronic myelogenous leukemia; HD = Hodgkin's lymphoma; IL-2 = interleukin-2; MDS = myelodysplastic syndrome; MIU = million international units; MM = multiple myeloma; NHL = non-Hodgkin's lymphoma. a Percentage of total number of patients in each study.
ment. The reason why lymphopenia occurs in vivo after high-dose IL-2 is unknown. Lymphopenia may result from margination and extravasation of lymphocytes. However, the dose-response curves of IL-2 and IFN-␣ reported in preclinical studies, including our data, strongly suggest the possibility that the down-regulation of NK cell activity observed at higher doses of these two cytokines could be due to the activation of a down-regulation pathway or to a cytotoxic effect on NK cells. Using IL-2 or IFN-␣, we up-regulated NK cell activity as early as 14 days post ASCT. Up-regulation of NK cell activity by each cytokine was observed in all engrafted samples. This finding is important because up-regulation of NK cell activity can be achieved as early as 14 days post ASCT to target minimal residual disease and possibly to prevent tumor relapses. In addition, the finding that upregulation of NK cell activity occurred with each cytokine pretransplantation supports the argument that NK cells retain their capability to respond to immunomodulators despite being treated with multiple chemotherapy drugs.
IL-2 has been used more often than IFN-␣ as a posttransplantation immunomodulator. Unfortunately, higher doses of IL-2 have been associated with serious complications, including death from capillary leak syndrome. Post-transplantation administration of low-dose IL-2 has been considered a means to achieve maximum immunomodulatory effect with minimal side-effects. Table 3 shows results of clinical studies in which low-dose IL-2 was given post transplantation. Results of these studies showed no grade 4 toxicity and minimal grade 3 toxicity. Lauria and colleagues 53 reported no relapses after 12 months of IL-2 therapy (median follow-up, 22 months; range, 10-42 months). Two patients who had residual disease after ABMT (one patient had disease in the liver and the second, in the lymph nodes) obtained a complete response after IL-2 therapy of 10 and 7 months, respectively. These data suggest that low-dose IL-2 has a low toxicity profile and some efficacy in delaying relapses post transplantation.
In summary, our study demonstrates up-regulation of NK cells with low-dose IL-2 or IFN-␣ as early as 14 days post ASCT. The available low toxicity profile data and therapeutic efficacy of low-dose IL-2 post ASCT and the results from our study suggest the rationale to develop studies to assess the efficacy of low-dose cytokines post ASCT to enhance immunologic recovery and activity (ie NK cells) to target minimal residual disease.
